Immunotherapy Experience in Bladder Cancer

Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.

Alternating two long-used bladder treatments cleared cancer in 24 of 25 patients whose disease had returned after BCG, an early study found. A larger trial comparing the approach with BCG alone is now enrolling.

Chester Freeman reflects on hiding the scars from his childhood tumor surgeries for decades and finally feeling comfortable in his own skin at 60.